SecSonar.com

NeoGenomics, Inc. (NEO)

NeoGenomics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

NeoGenomics, Inc. (NEO) is a Medical - Diagnostics & Research company based in US with a market capitalization of $276.4M. Revenue grew 10.1% year-over-year and free cash flow was negative at -$21.8M. This page tracks NEO's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 2.2K employees · IPO Mar 16, 2004

Valuation

Valuation & price

$8.24 · as of May 17, 2026 · -45.6% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

0.33

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$15.16$10.00$4.84Jul 25Dec 25Jul 26Jul 7, 25$7.31Jul 9, 25$7.53Jul 11, 25$7.26Jul 15, 25$6.90Jul 17, 25$6.72Jul 21, 25$6.21Jul 23, 25$6.61Jul 25, 25$6.29Jul 29, 25$5.25Jul 31, 25$4.84Aug 4, 25$5.67Aug 6, 25$5.49Aug 11, 25$5.82Aug 13, 25$6.24Aug 15, 25$6.21Aug 19, 25$6.31Aug 21, 25$6.18Aug 25, 25$6.45Aug 27, 25$7.08Aug 29, 25$8.78Sep 3, 25$8.19Sep 5, 25$7.98Sep 9, 25$7.86Sep 11, 25$8.34Sep 16, 25$7.99Sep 18, 25$8.62Sep 22, 25$8.40Sep 24, 25$7.87Sep 26, 25$7.93Sep 30, 25$7.72Oct 2, 25$8.98Oct 6, 25$9.10Oct 8, 25$9.17Oct 10, 25$9.10Oct 14, 25$9.38Oct 16, 25$10.28Oct 21, 25$10.43Oct 23, 25$10.45Oct 27, 25$10.16Oct 29, 25$10.28Oct 31, 25$9.77Nov 4, 25$10.10Nov 6, 25$10.40Nov 10, 25$10.40Nov 12, 25$10.00Nov 14, 25$10.34Nov 18, 25$10.41Nov 20, 25$10.60Nov 25, 25$12.34Nov 28, 25$12.10Dec 2, 25$12.07Dec 4, 25$12.17Dec 8, 25$11.71Dec 10, 25$12.00Dec 12, 25$11.85Dec 16, 25$11.67Dec 18, 25$11.68Dec 22, 25$12.42Dec 24, 25$12.30Dec 29, 25$12.30Jan 2, 26$11.76Jan 6, 26$12.80Jan 8, 26$12.83Jan 12, 26$12.49Jan 14, 26$13.22Jan 16, 26$12.79Jan 21, 26$12.69Jan 23, 26$12.81Jan 27, 26$12.47Jan 29, 26$12.40Feb 2, 26$12.31Feb 4, 26$11.97Feb 9, 26$11.35Feb 11, 26$11.45Feb 13, 26$11.38Feb 18, 26$10.26Feb 20, 26$9.89Feb 24, 26$9.65Feb 26, 26$10.17Mar 2, 26$9.50Mar 4, 26$9.10Mar 6, 26$8.96Mar 10, 26$8.56Mar 12, 26$7.98Mar 17, 26$8.27Mar 19, 26$8.18Mar 23, 26$8.10Mar 25, 26$7.77Mar 27, 26$7.19Mar 31, 26$7.42Apr 2, 26$8.00Apr 7, 26$8.06Apr 9, 26$7.94Apr 13, 26$8.00Apr 15, 26$8.68Apr 17, 26$8.35Apr 22, 26$8.18Apr 24, 26$8.29Apr 28, 26$9.02Apr 30, 26$9.26May 4, 26$9.00May 6, 26$8.89May 8, 26$8.96May 12, 26$8.75May 14, 26$8.36May 18, 26$8.37May 20, 26$8.90May 22, 26$9.23May 28, 26$10.19Jun 1, 26$10.44Jun 3, 26$10.14Jun 5, 26$10.90Jun 9, 26$11.44Jun 11, 26$11.47Jun 15, 26$11.09Jun 17, 26$10.38Jun 22, 26$11.20Jun 24, 26$12.90Jun 26, 26$14.17Jul 2, 26$15.16
$4.8452-week range$15.16
Loading valuation history…

Fundamentals

Key fundamentals

$276.4M

Market cap

10.1%

Revenue growth (YoY)

38.9%

Gross margin

-$21.8M

Free cash flow (USD)

$312.7M

Net debt

1.1%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$244.1MFY 2017$240.3MFY 2018$276.7MFY 2019$408.8MFY 2020$444.4MFY 2021$484.3MFY 2022$509.7MFY 2023$591.6MFY 2024$660.6MFY 2025$727.3M
$244.1M$727.3M

Free cash flow by year

2016 → 2025

FY 2016$13.9MFY 2017$4.3MFY 2018$30.5MFY 2019$3.3MFY 2020$-27.6MFY 2021$-90.9MFY 2022$-96.9MFY 2023$-30.7MFY 2024$-34.0MFY 2025$-21.8M
$13.9M-$21.8M

Gross margin by year

2021 → 2025

FY 202138.6%FY 202236.9%FY 202341.3%FY 202443.9%FY 202538.9%
38.6%38.9%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed Apr 28, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventDirector AppointmentJun 25, 2026Filing
  • 8-K eventConvertible Notes IssuedJun 22, 2026Filing
  • 8-K eventConvertible Notes OfferingJun 17, 2026Filing
  • 8-K eventConvertible Notes OfferingJun 15, 2026Filing
  • 8-K eventEquity Incentive Plan AmendmentMay 22, 2026Filing
  • 8-K eventEarnings ReleaseApr 28, 2026Filing
  • Quarterly report10-Q FiledApr 28, 2026Filing

Questions

Frequently asked questions

What is NeoGenomics, Inc.'s market cap?

NeoGenomics, Inc. (NEO) has a market capitalization of $276.4M.

What is NEO's P/E ratio?

A meaningful P/E ratio is not available for NEO — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is NEO's price-to-book (P/B) ratio?

NEO trades at 0.33 times book value per share.

Are insiders buying NEO stock?

SEC Form 4 filings show no open-market insider buys at NeoGenomics, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Medical - Diagnostics & Research

PRE

Prenetics Global Limited

$360.1M

MYGN

Myriad Genetics, Inc.

$378.3M

IMDX

Insight Molecular Diagnostics Inc.

$173.1M

BDSX

Biodesix, Inc.

$129.6M

ATLN

Atlantic International Corp.

$122.2M

XGN

Exagen Inc.

$119.6M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.